NCCN 2016 Congress Webinar Series: Lung Cancer - Treatment of Older Adult Patients with Non-Small Cell Lung Cancer
This series is designed to educate healthcare professionals on current and emerging scientific data so that they can make evidence-based decisions about screening and treatment for patients with non-small cell lung cancer (NSCLC). The goal of this series is to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists, and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practices and healthcare settings for patients with NSCLC.
This educational program is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with non-small cell lung cancer.
Following this activity, participants should be able to:
- Apply into practice tools--such as risk factor algorithm, frailty assessment, geriatric assessment, and performance status--to assess whether older patients with NSCLC can tolerate certain therapeutic interventions.
- Assess the risks and benefits of therapeutic interventions in the management of older patients with NSCLC who are at higher risk for adverse events from therapy.
Neelesh Sharma, MD, PhD
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center and
Cleveland Clinic Taussig Cancer Institute
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below have disclosed the following relevant financial relationships:
Neelesh Sharma, MD, PhD
Astellas: Grant/Research Support
Boehringer Ingelheim GmbH: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
GlaxoSmithKline: Grant/Research Support
Incuron Inc: Grant/Research Support
Mirati Therapeutics: Grant/Research Support
Nanocarrier: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Plexxikon: Grant/Research Support
NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith, CMP, CHCP; Jennifer McCann Weckesser
The activity planning staff listed below has the following relevant financial relationships to disclose:
Mercedes De La Hoz
Pfizer, Inc.: Other financial benefit
The NCCN clinical information team listed below, who has reviewed content, has no relevant financial relationships to disclose:
Ellen Erkess; Kristina M. Gregory, RN, MSN, OCN; Miranda Hughes, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.0 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.
Universal Activity Number: 0836-0000-16-076-L01-P
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation